Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
Intravacc secures $633K funding from CARB-X to develop a vaccine against Neisseria gonorrhoeae.
We are thrilled to announce the launch of our new website!
In vitro alternative assay to the replace rabbit pyrogen test for vaccines.
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China
Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine
Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine
